Randomised Controlled TrialiVNS

Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study

Peterson D, Van Poppel M, Boling W, Santos P, Schwalb J, Eisenberg H, Mehta A, Spader H, Botros J, Vrionis FD, et al.

Bioelectronic Medicine · 2024

Key finding

Sixty patients were implanted during Stage 1 of the study.

Condition
Rheumatoid Arthritis
Stimulation
iVNS
Evidence tier
Randomised Controlled Trial
Participants
View on DOI

Cite this study

Peterson, D., Van Poppel, M., Boling, W., Santos, P., Schwalb, J., Eisenberg, H., Mehta, A., Spader, H., Botros, J., Vrionis, F. D., Ko, A., Adelson, P. D., Lega, B., Konrad, P., Calle, G., Vale, F. L., Bucholz, R., & Richardson, R. M. (2024). Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectronic Medicine, 10(1). https://doi.org/10.1186/s42234-023-00138-x

Related studies in Rheumatoid Arthritis

Summary by Vagus Research. Always consult the primary source for the authoritative record.

Stay Current with the Research

Join researchers and practitioners exploring the science of vagus nerve stimulation. Receive curated research summaries and evidence updates.

No spam. Unsubscribe at any time. We respect your privacy.